Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7440938 | 0.85 | HPGD (0.44) | ALDH1A1HPGDTSHRNPSR1TP53 | |
| SCHEMBL7440965 | 0.85 | ADA (0.49) | ADORA2AADORA2BALDH1A1TSHRLMNA | |
| SCHEMBL7442757 | 0.79 | ADORA2A (0.36) | ADORA2AADORA2BALDH1A1HPGDTSHR | |
| SCHEMBL8140043 | 0.72 | PDE5A (0.60) | ALDH1A1HPGDCASP1CASP7MAPT | |
| SCHEMBL25095261 | 0.71 | ADORA2A (0.49) | ADORA2AADORA2BTSHRMAPK1ADORA1 | |
| SCHEMBL20624337 | 0.71 | ADORA2A (0.49) | ADORA2AADORA2BTSHRMAPK1ADORA1 | |
| SCHEMBL21992893 | 0.71 | ADORA2A (0.49) | ADORA2AADORA2BTSHRMAPK1ADORA1 | |
| SCHEMBL21992894 | 0.71 | ADORA2A (0.49) | ADORA2AADORA2BTSHRMAPK1ADORA1 | |
| SCHEMBL6051984 | 0.71 | HPGD (0.42) | ALDH1A1HPGDTSHRNPSR1MAPK1 | |
| SCHEMBL7442592 | 0.71 | HPGD (0.38) | ADORA2AADORA2BALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6440981-B1 | REGULATING APOPTOSIS IN HUMAN CELLS COMPRISING EXPOSING SAID CELLS TO AN EFFECTIVE AMOUNT OF A 2,9-DISUBSTITUTED PURINE-6 ONE COMPOUND | CELL PATHWAYS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020032209-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones | OSI PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | disclosed |
| US-6268372-B1 | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones | CELL PATHWAYS, INC. | 2001-07-31 | — | — | US | disclosed |
| US-5861404-A | ANTIINFLAMMATORY AGENTS, THROMBOEMBOLIC AND CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-19 | — | — | US | disclosed |
| EP-0722944-A1 | 2-9-Disubstituted Purin-6-ones | BAYER AG (DE) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032209-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones | MKI67, PCNA, HRAS | ADORA2A 1817/4885ADORA2B 1508/4885ALDH1A1 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.